Tolcapone-Ro-40-7592-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemETolcaponeCat. No.: HY-17406CAS No.: 134308-13-7Synonyms: Ro 40-7592分式: CHNO分量: 273.24作靶點: COMT作通路: Metabolic Enzyme/Protease; Neuronal Signaling儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO

2、 : 100 mg/mL (365.98 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.6598 mL 18.2989 mL 36.5979 mL5 mM 0.7320 mL 3.6598 mL 7.3196 mL10 mM 0.3660 mL 1.8299 mL 3.6598 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內(nèi)實驗 請根據(jù)您的實驗動物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前請先配制澄清的儲備液，再依次添加助溶?為保證實驗結(jié)果的可靠性，體內(nèi)

3、實驗的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (9.15 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (9.15 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師

4、www.MedChemEBIOLOGICAL ACTIVITY物活性 Tolcapone(Ro 40-7592)服活性的外周 和中樞COMT抑制劑。REFERENCES1. Neil E. Paterson, Jennifer Ricciardi, Caitlin Wetzler, et al. Sub-optimal performance in the 5-choice serial reaction time task in rats wassensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffecte

5、d by the COMT inhibitor tolcapone. Neuros2. Saviana Di Giovanni, Simona Eleuteri, Katerina E. Paleologou, et al. Entacapone and Tolcapone, Two Catechol O-MethyltransferaseInhibitors, Block Fibril Formation of -Synuclein and -Amyloid and Protect against Amyloid-induced Toxicity. The Journal of Bi3. P

6、anos Bitsios, Panos Roussos1. Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia.Pharmacogenomics. 2001,12 (4): 559-566.4. M.A. Vieira-Coelho, P. Soares-da-Silva. Ontogenic aspects of liver and kidney catechol-O- methyltransferase sensitivity to tolcapone.British Journal of

7、 Pharmacology.1996,117 (3):516-520.5. J. Dingemanse, K. Jorga, G. Zurcher,et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone andsingle-dose levodopa. British Journal of Clinical Pharmacology 1995, 40 (3):253-262.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use